REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > In Vivo Diagnosis Or In Vivo Testing > Testing Efficacy Or Toxicity Of A Compound Or Composition (e.g., Drug, Vaccine, Etc.) Testing Efficacy Or Toxicity Of A Compound Or Composition (e.g., Drug, Vaccine, Etc.)Testing Efficacy Or Toxicity Of A Compound Or Composition (e.g., Drug, Vaccine, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/26/07 - 20070172425 - Testing cell cycle regulation effect of a compound using a hollow fibre cell implant The invention includes an in vivo pharmacodynamic method for testing a compound for cell cycle regulation. ... 07/19/07 - 20070166230 - Ion channel Provided are Kv9.2 polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding Kv9.2 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, ... 07/12/07 - 20070160539 - Hprp4s modifiers of the p53 pathway and methods of use Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided. ... 07/12/07 - 20070160538 - Antianxiety drugs and a method of screening the same An anxiolytic drug of the invention comprises an orexin receptor antagonist, a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient. A method for screening a compound having an anxiolytic action of the invention comprises a step of using orexin-A. ... 07/12/07 - 20070160537 - In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis ... 07/05/07 - 20070154393 - Bioassay for volatile low molecular weight insecticides and methods of use The subject invention pertains to materials and methods for screening of volatile insecticides for activity against pests, such as those that pose a threat to public health (e.g., dipterans such as flies and mosquitoes). One aspect of the invention pertains to an apparatus and bioassay for screening volatile compounds for ... 06/28/07 - 20070148093 - Non-terminal method of identifying anti-migraine compounds The present invention relates to in vivo non-terminal method of identifying anti-migraine compounds. ... 06/21/07 - 20070140969 - Method for comparing botulinum neurotoxins Skin topographical methods for quantifying pharmacodynamic parameters of a paralytic effect of a Clostridial toxin, such as a botulinum toxin upon a muscle, such as a frontalis muscle. The methods are effective in determining the potency of a Clostridial toxin, and in comparing toxins. For example, wrinkle reduction effects caused ... 06/21/07 - 20070140968 - Method for determining botulinum potency Skin topographical methods for quantifying pharmacodynamic parameters of a paralytic effect of a Clostridial toxin, such as a botulinum toxin upon a muscle, such as a frontalis muscle. The methods are effective in determining the potency of a Clostridial toxin, and in comparing toxins. For example, wrinkle reduction effects caused ... 06/14/07 - 20070134158 - Method for comparing multiple botulinum neurotoxins Skin topographical methods for quantifying pharmacodynamic parameters of a paralytic effect of a Clostridial toxin, such as a botulinum toxin upon a muscle, such as a frontalis muscle. The methods are effective in determining the potency of a Clostridial toxin, and in comparing toxins. For example, wrinkle reduction effects caused ... 06/14/07 - 20070134157 - Biological assay The invention is a method for determining an in vivo cardiac electrophysiology profile of a compound affecting one or more cardiac ion channels which comprises administering the compound to a rat, and simultaneously measuring one or more periods selected from the group consisting of an atrial refractory period, a ventricular ... 06/14/07 - 20070134156 - Fatigue evaluation apparatus, fatigue evaluation method, and application thereof The present invention provides a method for easily and quantitatively evaluating a degree of fatigue of a human being, a kit therefor, and an application thereof. Specifically, by measuring a concentration of amino acid in plasma taken from a subject, the degree of fatigue of the subject in daily life ... 05/24/07 - 20070116645 - Methods and compositions for inhibiting cholesterol uptake The present invention is directed to a method for the lowering of levels of LDL cholesterol in an individual comprising administering to the individual an agent which modulates the activity of the protein annexin 2, cyclophilin A, cyclophilin 40, or HSP 56 or the complex of annexin 2 and caveolin ... 05/03/07 - 20070098637 - Generation and use of vasculogenic tumors and products derived from same Tumors can be directed into a vasculogeinc program and used to regenerate tissues in a verterbrate host, identify factors originating from the tumor that are useful for tissue regeneration, and to generate such factors for use in a subject apart from the tumor itself. ... 05/03/07 - 20070098636 - Method of identifying responders to treatment with insulin sensitizers A patient who is a responder to a therapeutic treatment for insulin resistance or for one or more diseases associated with type 2 diabetes can be identified by the method of measuring the amount of HMW adiponectin and the amount of total adiponectin or LMW adiponectin in the patient's tissue ... 05/03/07 - 20070098635 - Secreted polypeptide species associatedwith cardiovascular disorders The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and treatment of cardiovascular disorders. ... 04/26/07 - 20070092449 - Methods for direct visualization of active synapses A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells ... 04/26/07 - 20070092448 - Inhibitor screening method and atopic dermatitis-like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same The present invention provides methods which use induction phenomenon of production of interleukin 18 (IL-18) from keratinocyte (KC), and their usages. The methods are preferably applicable for understanding of pathogenic mechanisms of atopic dermatitis (AD) and AD-like symptoms, and for development of therapeutic drugs for AD and AD-like symptoms. For ... 04/19/07 - 20070086947 - System and method for selecting a pillow and mattress A method is provided for selecting a pillow and mattress based upon an empirical measurement of an individual's pillow selection criteria, mattress selection criteria and sleep characteristics. A system incorporating the principles of the method are also disclosed. ... 04/19/07 - 20070086946 - Assay The present invention relates, in general, to a method of assaying an immune response induced by an immunogen, and, more particularly, to a method of assaying a immunogen for its ability to induce a desired immune response, wherein the assay is effected in an autoimmune animal. ... 04/05/07 - 20070077205 - Use of non-invasive imaging technologies to monitor in vivo gene-expression The present invention provides methods of using non-invasive imaging technologies to monitor the effects of potential therapeutic compounds on gene expression in non-human living animals. This invention also provides methods to analyze perturbation in biochemical pathways and physiological functions associated with disease (e.g., a cancer, cardiovascular disease, degenerative nervous system ... 04/05/07 - 20070077204 - Olfactory identification tests for cognitive diseases and disorders The present invention provides smell tests (odor identification tests) that are shorter that UPSIT, yet has a statistical sensitivity and specificity equivalent to or better than UPSIT. The odor identification tests of the invention are based on a core set of six odorants, where the six odorants can be selected ... 04/05/07 - 20070077203 - Surrogate markers The invention provides a method to analyze an effect of a biological insult such as exposure to ionizing radiation comprising (a) exposing one or more groups of subjects to a biological insult of at least about an LD10 to obtain one or more groups of exposed subjects; and (b) measuring ... 03/29/07 - 20070071682 - Methods for testing vaccine candidates against bacterial infection in rodents Methods and a rodent model to test the effectiveness of vaccine candidates against bacteria, e.g., Staphylococcus aureus by systemically immunizing a rodent, particularly a cotton rat, with a vaccine candidate, intranasally challenging the cotton rat with the selected bacteria, and detecting a response with respect to an immune response, nasal ... 03/29/07 - 20070071681 - Apparatus and method for computer modeling type 1 diabetes The invention encompasses novel methods for developing a computer model of type 1 diabetes in a mammal. In particular, the models can include representations of biological processes associated with a pancreatic lymph node and one or more pancreatic islets. Alternatively, the models can include representations of biological processes associated with ... 03/15/07 - 20070059243 - Method of treating or inhibiting the development of brain inflammation and sepsis A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid ... 03/01/07 - 20070048225 - Nk3 receptor in vivo assay The present invention relates to a method of assessing the in vivo potency of a NK3 receptor antagonist comprising: a) the non-human animal with the NK3 receptor antagonist of interest, b) treating an non-human animal with a NK3 R agonist treating, c) measuring the activity of the treated non-human animal, ... 02/22/07 - 20070041905 - Method of treating depression using a tnf-alpha antibody The invention describes methods of treating depression comprising administering a TNFα antibody, such as a human TNFα antibody. The invention also provides a method for treating depression comprising inhibiting TNFα activity in a subject suffering from depression by systemically administering to the subject a human anti-TNFα antibody, or an antigen-binding ... 02/01/07 - 20070025916 - Porcine helicobacter infection Compositions and methods for treating, preventing and diagnosing Helicobacter infection are disclosed. The methods use proteins and/or nucleic acids derived from Helicobacter cerdo, a new pathogen isolated from swine. In addition, porcine models for studying bacterial gastritis and gastric and duodenal ulcer disease caused by Helicobacter pathogens, such as H. ... 01/11/07 - 20070009439 - Diabetogenic rat model The present invention provides a method of producing diabetic rats, and a method for identifying compounds that reverse diabetes in said rats. ... 12/28/06 - 20060292076 - Antimicrobial mediated ozone generation The invention provides methods of detecting antibodies and neutrophils that can generate reactive oxygen species. ... 12/21/06 - 20060286036 - Methods and compositions for inhibiting hiv infection This invention provides novel methods for identifying agents that inhibit HIV infection. The anti-HIV agents are identified by screening test compounds for ability to modulate a biological activity of isopeptidase T (IsoT), e.g., its isopeptidase activity or its binding to another molecule such as viral protein R (Vpr). Such IsoT ... 12/21/06 - 20060286035 - Methods and compositions for modulating the interaction between adiponectin and its receptor The invention is directed to methods for identifying agents that mimic or modulate the interaction between adiponectin and its receptor. In particular, the invention is directed to methods for mimicking or modulating the adiponectin-T-cadherin interaction in order to treat diseases and disorders associated with a deficiency or overabundance of adiponectin. ... 12/21/06 - 20060286034 - Oligosaccharide biomarkers for mucopolysaccharidoses and other related disorders The present invention is related to methods for diagnosing mucopolysaccharidoses (“MPS”) and related diseases. This invention pertains to methods for identifying and quantitating biochemical markers (“biomarkers”) that are present in biological fluids or tissues of a patient having a MPS or related disorder. One aspect of the method comprises determining ... 12/14/06 - 20060280686 - Method of measuring the biological activity of an urotensin ii receptor Administration of U-II to rats caused an increase in the redness or the skin temperature of the ear of the rats. The increase was inhibited by compounds that decease the biological activity of the U-II/UT receptor. Thus, the present invention provides methods of measuring the biological activity of an U-II ... 12/14/06 - 20060280685 - Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in ... 12/14/06 - 20060280684 - Methods utilizing novel target genes related to immune-mediated diseases The present invention provides methods utilizing novel target genes related to immune-mediated diseases, such as asthma, allergy and autoimmune diseases. The invention is based on a molecular level description of the polarization of CD4+ precursor cells (Thp) from which T helper cells are known to originate. Particularly, the present invention ... 11/30/06 - 20060269482 - Cyclin-dependent kinase inhibition of rb phosphorylation Methods for testing and assessing whether an agent that inhibits cdk activity produces a therapeutic response in a mammal, with a focus on detecting the inhibition of phosphorylation of the retinoblastoma protein (Rb) at putative phosphorylation sites, are disclosed. Also disclosed are methods for monitoring pharmacodynamic drug action of a ... 11/23/06 - 20060263299 - Effect of substances on sexual function A preclinical animal model and method of using same to evaluate the effects of various substances (or quantities of substances), such as antidepressants, on sexual function in humans and other mammals is disclosed. Also disclosed are compositions comprising the substances evaluated by the present invention and method for using same ... 11/23/06 - 20060263298 - Assay The present invention relates to an ex vivo plaque rupture model and methods of use thereof, in particular as a screen for atherosclerosis plaque stabilizing drugs. The invention also relates to an apparatus used in the model and methods of use thereof. ... 11/16/06 - 20060257319 - Method for in vivo determination on tested animals of the efficient concentration of deuterium depleted water for cancer therapy Deuterium Depleted Water is administered to tested animals before and after tumoral grafting with animal grafts in certain concentrations over a period of time, viability is determined for the tumor cells to be grafted, grafting of the animals in the experimental group and the control animals is conducted, continuously and ... 10/19/06 - 20060233711 - Method for treating conditions associated with fear memory A method of treating conditions associated with fear memory in a mammal is provided which includes selective inhibition of a GluR6 receptor. Methods of screening for compounds useful to treat such conditions are also provided. ... 10/19/06 - 20060233710 - Prevention and treatment for gvhd The present invention is to provide a method for avoiding specifically and preventively or therapeutically an organ injury in graft-versus host disease (GVHD), a preventive or therapeutic agent therefore, and a method for screening the preventive or therapeutic agent. By inhibiting the interaction between fractalkine and the chemokine receptor CX3CR1 ... 10/19/06 - 20060233709 - Method for identifying novel treatments of inflammatory disease in the gut Model fish and use thereof for screening for the presence of gut inflammatory disease, especially in zebrafish. Induction of the disease state and visualization of the gastrointestinal tract in living zebrafish. Visualization of the inflammatory state in vivo facilitates screening for compounds that can be used in treatment of inflammatory ... 10/12/06 - 20060228303 - Method of screening for genes that influence pathological conditions or survival of animals infected with pathogen Efficient screening of genes that influence pathological conditions or survival of animals infected with pathogen is enabled by the use of a full-length cDNA library as DNAs for immunizing animals in place of a genomic DNA library, used in the conventional ELI method. ... 10/12/06 - 20060228302 - Directed complementation A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary ... 10/05/06 - 20060222590 - Directed complementation A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary ... 10/05/06 - 20060222589 - Directed complementation A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary ... 09/21/06 - 20060210477 - Therapeutic agent for cancer There is provided a therapeutic agent for cancer mainly comprising a saccharide having an α1→3 steric structure where an action of NKT cells on NKR-P1 (natural killer receptor P1) which is a natural killer (NK) cell antigen receptor of NKT cells in an activating ability of natural killer T (NKT) ... 09/21/06 - 20060210476 - Metabonomics homogeneity analysis A metabonomic method of selecting one or more non-human primate subjects for inclusion in a study is disclosed. The method generally involves spectroscopically profiling a sample of bodily fluid acquired from a subject proposed to be included in the study. The subject is accepted or rejected as a member of ... 09/07/06 - 20060198789 - Target validation assay An method of determining whether a gene of interest is necessary for a tumor cell to maintain its tumorigenicity is disclosed. The method is useful for validation of cancer therapeutic targets in vivo, using shRNAs and tumor xenografts. The inducible shRNA method operates an in vivo RNAi competition assay. ... 09/07/06 - 20060198788 - Method of evaluating compound efficacious in treating obesity by using slc25a10 Evaluation of compounds including screening of therapeutic agents for obesity is performed utilizing expression levels of Slc25a10 gene or protein in a test tissue or a test cell, or utilizing the nature of Slc25a10 gene or protein. Examination of obesity is performed based on expression levels of Slc25a10 gene or ... 08/31/06 - 20060193777 - Method of screening compounds for potential efficacy for the treatment of signs of aging The present invention features a method of screening a compound for potential efficacy for the treatment of at least one sign of aging on the skin selected from the group consisting of enhancing the elasticity of said skin, enhancing the firmness of said skin, or reducing the appearance of wrinkles ... 08/31/06 - 20060193776 - Screening methods employing zebrafish and the blood brain barrier Use of fish, in particular zebrafish, in screening for substances with an ophthalmological effect or biological effect on the brain or central nervous system and/or effect on a disease or disorder of the brain or central nervous system. Based on identification and characterisation of the blood brain barrier. ... 08/24/06 - 20060188445 - Assay for compounds that protect against sensory hair cell death and compounds identified by same The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects. ... 08/17/06 - 20060182686 - Developmental animal model of temporal lobe epilepsy Disclosed is a developmental animal model of temporal lobe epilepsy and other seizure-related disorders. In particular, the invention provides a method of inducing a permanent change in the neurological development of a rodent, such as a rat, comprising daily administration of low doses of a kainate receptor agonist to the ... 08/17/06 - 20060182685 - Hollow fiber technique for in vivo study of cell populations The present invention relates to a method of using hollow fibers to evaluate cellular changes in vivo. A method for evaluating cellular changes in vivo in response to administration of a drug or drugs of interest is provided. The hollow fiber technique is also used to evaluate cellular changes in ... 08/03/06 - 20060171890 - Methods for evaluating the activity of candidate agents Methods for evaluating the activity of candidate agents are provided. In practicing the subject methods, a candidate agent is administered to an injured tissue site of an animal and the activity of the candidate agent on the injured tissue site is evaluated. Also provided are kits and systems for use ... 07/27/06 - 20060165596 - Method and apparatus for noninvasively evaluating endothelial function The present invention relates to assessing and measuring endothelial functions. A vasodilating stimulant is provided to a patient to stimulate hemodynamic activity in a selected region of the patient's body. In an embodiment, endothelial function may then be assessed by monitoring a change in a hemodynamic parameter at the selected ... 07/27/06 - 20060165595 - In vivo angiogenesis assay A method for evaluating in vivo a test substance for angiogenesis modulation activity, including the steps of providing a rodent pup having a pupillary membrane system in a first eye, injecting transcorneally proximate to the pupillary membrane a test substance; and examining the pupillary membrane to determine whether new vascular ... 07/20/06 - 20060159623 - Stem cells for use in locating and targeting tumor cells A composition for locating tumors, the composition includes stem cells. Stem cells for use in locating and treating tumors. A method of locating and treating a tumor by administering to a patient an effective amount of stem cells, wherein the stem cells locate and subsequently treat a tumor. ... 07/20/06 - 20060159622 - Pharmacodynamic assay for inhibitors of 11-beta-hydroxysteroid dehydrogenase activity in animal tissues A novel method is provided to measure 11β-hydroxysteroid dehydrogenase activity in intact whole animal tissues in the presence of systemically or ex vivo administered inhibitors of the enzyme. Inhibitors of the type 1 isoform (11β-HSD1) may be useful to treat type 2 diabetes, Metabolic Syndrome, and other metabolic disorders. ... 07/13/06 - 20060153772 - Contextual fear conditioning for predicting immunotherapeutic efficacy The invention provides methods for determining effective immunotherapeutic agents which may be used for the treatment of cognitive disorders. ... 07/06/06 - 20060147377 - Animal model for the fast identification of pharmaceutical active compounds in vivo In a first aspect the present invention provides a tumor cell line stably transfected with an expression vector containing a reporter gene, preferably a fluorescent protein, operably linked to a promotor that also controls expression of a protein that is associated with tumor regression, stabilisation of tumor growth or inhibition ... 06/29/06 - 20060140862 - Fish hatching method and apparatus The invention is a method and kit for conducting a rapid toxicity test. Methods and kits according to the invention include an animal or plant species in diapause. ... 06/15/06 - 20060127312 - Notch signaling in long-term memory formation The present invention is directed to a method of modulating (e.g., enhanced, increased) long term memory formation in an animal comprising modulating Notch function (e.g., Notch protein expression) in said animal. In addition, the present invention is directed to a method of treating an animal with a defect in long ... 06/08/06 - 20060120963 - Method of identifying therapeutic compounds for a treatment of hepatic disorders The present invention relates to methods of identifying potentially therapeutic compounds for the treatment of hepatic disorders, preferably alcohol-induced hepatitis. Further, use of mammals in such methods, therapeutic compounds identified using said methods and the use of a Chinese Herb, CH-100, in the treatment of hepatic disorders, particularly alcohol-induced hepatic ... 06/08/06 - 20060120962 - Cardiac safe, rapid medication delivery The disclosure provides methods and compositions for providing an effective dose of an active agent and/or drug composition to a subject by inhalation. The methods of the disclosure are useful in determining a maximal effective dose that limits cardiovascular damage upon inhalation. ... 05/18/06 - 20060104905 - Methods of screening agents for activity using teleosts The present invention provides methods of screening an agent for activity using teleosts. Methods of screening an agent for angiogenesis activity, toxic activity and an effect cell death activity in teleosts are provided. ... 05/18/06 - 20060104904 - Method of evaluating plant protection A method is provided for evaluating a protected plant having a protection mechanism. A population of immature insects (i.e., larvae or nymphs) belonging to an insect species having a plurality of instars is first exposed to the protected plant such that the protected plant is at least contacted thereby. The ... 05/18/06 - 20060104903 - Model for evaluating the efficacy of locally applied antiproliferatives or other agents on neointimal hyperplasia, immunohistochemical and vascular cell cycle changes in balloon-injured rat carotid arteries A methodology for evaluating the efficacy of locally applied antiproliferatives and/or other therapeutic agents on neointimal hyperplasia, as well as immunohistochemical and vascular cell cycle changes, in balloon-injured rat carotid arteries may be utilized for determining the efficacy of treatments in humans. ... 04/27/06 - 20060088473 - Treatment screening methods The invention includes a method to identify a method to enhance survival of a subject such as a non-human primate that has been exposed to a biological insult such as an ionizing radiation dose of about LD30/30 or about LD50/30 by treating the exposed subject with a test compound an ... 04/27/06 - 20060088472 - E7 regulation of p21 cip1 through akt Disclosed are compositions and methods for inhibiting E7 effects on Akt, such as preventing the nuclear localization of p21Cip1. ... 04/20/06 - 20060083686 - Therapeutic agent for ulcerative colitis Disclosed are pharmaceutical compositions of treatment for a patient with ulcerative colitis comprising a drug which can selectively kill Fusobacterium varium cells, or a drug which can neutralize the toxin produced by Fusobacterium varium cells, a method for screening such a drug, a method for treating a patient with the ... 04/13/06 - 20060078499 - Use of hedgehog agonist to treat depression This invention provides methods for determining whether an agent, known to upregulate the sonic hedgehog pathway, increases brain progenitor cell division in a subject. Furthermore, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive ... 04/13/06 - 20060078498 - Methods for the identification of novel ligands for the g protein-coupled receptor (gpcr) 192 The present invention relates to methods for the identification and characterization of polypeptides with ligand activity for the G protein coupled receptor (GPCR) 192. The invention encompasses the use of the ligands in combination with the receptor for the development of assays/kits for the identification of molecules that affect the ... 04/06/06 - 20060073099 - Treatment screening methods The invention includes a method to identify a method to enhance survival of a subject that has been exposed to a biological insult such as an ionizing radiation dose of LD50/30 by treating the exposed subject with a test compound an optically comparing the results to that obtained using control ... 03/30/06 - 20060067888 - Immunogenic glycopeptides, screening, preparation and uses The invention relates to immunogenic glycopeptides derived from pathogenic microorganisms, which can be used for immunization and diagnosing infections dye to such pathogenic microorganisms and also to method for the selection and preparation thereof. ... 03/09/06 - 20060051295 - Estrogen receptor interaction with a transcription factor The invention provides a method to measure a direct interaction between an estrogen receptor and a transactivation protein in an in vitro system by providing for a detection parameter proportionally related to the degree of the interaction, whereby the transactivation protein is c-Rel. In an embodiment of the invention a ... 03/02/06 - 20060045847 - Method for determination of anabolic activity Novel methods for determining the anabolic activity of a compound in muscle using microarrays to compare the in vivo changes of the genomic profile of mammalian muscle induced by a tested compound versus the corresponding changes induced by a known anabolic steroid. For example, in vivo changes of the genomic ... 02/23/06 - 20060039862 - Identification and use of growth hormone secretagogue receptor type 1a antagonists Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake. ... 02/16/06 - 20060034764 - Fusion proteins of mycobacterium tuberculosis antigens and their uses The present invention relates to fusion proteins containing at least two Mycobacterium tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five ... 02/16/06 - 20060034763 - Therapeutic use of resveratrol for hyperglycemia The resveratrol, an antioxidant found in various fruits, vegetables, grapes, and red wines, has been shown to have free radical scavenging, anti-inflammatory and anti-thrombogenic activities in the biological systems. Moreover, resveratrol has also been shown to be a good cancer preventive chemical and has been recommended as a food supplement ... 02/02/06 - 20060024234 - Protein markers for pharmaceuticals and related toxicity Protein markers of toxicity and efficacy for antilipemic drugs are determined. Methods and reagents are disclosed for determining whether a patient receiving an antilipemic drug, especially a statin or HMGCoA reductase inhibiting drug, is experiencing drug efficacy and/or toxicity. Individual susceptibility is also determined prior to treatment. Also, drug discovery ... 01/26/06 - 20060018834 - Imaging sexual response The present invention relates to methods for contrast-enhanced imaging of sexual response. In particular, the present invention relates to methods of magnetic resonance imaging (MRI), computerized X-ray tomography (CT), ultrasound, and optical imaging using contrast agents to measure blood flow during sexual response, especially female sexual response. The invention relates ... 01/26/06 - 20060018833 - Method and system for screening compounds for muscular and/or neurological activity in animals Screening methods and instrumentation for candidate pharmacological agents are applied to discover compounds with muscular and/or neurological activity. The method comprises the use of teleost fish, such as the medaka (Oryzias latipes), which may be stimulated with chemical agents or an electric field to produce, for example, seizure activity and/or ... 01/19/06 - 20060013770 - Method for screening for compounds as potential sedatives or anxiolytics The present invention relates to a method for screening a chemical compound for its potential as a sedative or anxiolytica. The invention also relates to a drug development method and to the use of a compound as identified by the screening method for the treatment, prevention or alleviation of anxiety, ... 12/22/05 - 20050281745 - Stable isotope based dynamic metabolic profiling of living organisms for characterization of metabolic diseases, drug testing and drug development The metabolic processes involved in the formation of any glucose-based metabolite of a metabolic network are determined. A precursor molecule is labeled with a stable carbon (13C) isotope at specific positions. The label is allowed to distribute and rearrange in the system. Metabolites are recovered and analyzed against a control ... 12/22/05 - 20050281744 - Method for assessing the effect of a drug on long term memory formation Methods of assessing the effect of a drug on long term memory and for screening a pharmaceutical agent for its ability to modulate long term memory are disclosed. ... 12/22/05 - 20050281743 - Cancer associated protein phosphatases and their uses Detection of expression of the provided phosphatases in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and for determining patient prognosis. The encoded polypeptides further provide a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells. The present invention further ... 12/15/05 - 20050276758 - Method for screening agents against human prostate disease Isolated polynucleotides encoding Cynomolgus monkey prostate specific antigen and polypeptides obtainable from the polynucleotides and uses are disclosed. ... 12/15/05 - 20050276757 - Methods of using zc1 and zc3 kinase substrate phosphorylation as biomarkers The present invention provides novel biomarkers for cancer: the phosphorylation of ZC1 and/or ZC3 kinase substrates, particularly p120 catenin and Abi-1. Accordingly, the invention provides methods of determining whether a compound modulates ZC1 or ZC3 kinase activity, methods of determining whether a mammal is responding to a compound that modulates ... 11/24/05 - 20050260135 - High throughput pharmaceutical screening using drosophila High throughput drug screening assay methods and related apparatus are described. Wild-type Drosophila are raised in multi-well microtiter plates on a growth medium having a high level of a sugar such as glucose. The high sugar diet during development induces screenably distinct characteristics in the wild-type Drosophila. Compounds that putatively ... 11/24/05 - 20050260134 - Process, system, and kit for evaluating the relief of the skin with a substrate A process, system, and kit for evaluating the relief of the skin using a substrate with an adhesive surface. The process includes the steps of applying the substrate onto a test zone of the skin so that the adhesive surface is in contact with the skin at contact locations; removing ... 11/10/05 - 20050249666 - Establishment of human cancer cell lines with metastatic potential using nod/scid The invention provides a new reproducible transgenic mouse model for the study of tumor metastasis. In particular, the invention concerns the study of tumor metastasis in a NOD/SCID/γcnull transgenic mouse model. ... 11/03/05 - 20050244335 - Methods and compositions related to increasing antitumor activity of chemotherapeutic agents Disclosed are methods and compositions related to increasing antitumor activity of chemotherapeutic agents. ... 10/27/05 - 20050238581 - Dynamic hepatic recycling glucose tolerance test Systems and methods are described providing a hepatic recycling glucose tolerance test for the diagnosis of types and subtypes of diabetes mellitus and other hyperglycemic or hypoglycemic conditions. A method is also provided for screening candidate drugs for treating various types of abnormal glucose metabolism and to monitor whether the ... 10/20/05 - 20050232863 - Longevity and papp-a This document provides materials and methods related to PAPP-A polypeptides, aging, and transgenic non-human mammals whose genomes comprise a disrupted PAPP-A allele. Methods for making such transgenic non-human mammals, and using them and other mammals to identify and characterize agents that affect conditions related to PAPP-A activity, such as vascular ... 10/06/05 - 20050220710 - Overfeeding methods for determining therapeutic strategies and/or targets for obesity therapeutics Methods for determining therapeutic strategies and/or targets for examining weight loss in an individual, comprising administering to the individual a prolonged overfeeding regimen and identifying gene and/or protein expression that occur in the individual with the prolonged overfeeding regimen. ... 09/29/05 - 20050214220 - Tumor model The present invention relates a method of forming an orthotopic solid tumor in a host. The method includes the step of introducing transformed cells into an orthotopic site in the host and allowing the introduced cells to form a tumor. The cells introduced into the orthotopic site are transformed by ... 09/29/05 - 20050214219 - 24p3 receptors and uses thereof A receptor for 24p3 has been identified. The receptor has been found to play a role in both iron transport and apoptosis. Accordingly, compounds that modulate the expression or activity of a 24p3R are useful for modulating iron transport and apoptosis. ... 09/15/05 - 20050201938 - Method for selectively inhibiting ghrelin action The present invention provides a method selectively inhibiting ghrelin activity to treat a variety of diseases including obesity and related disorders, particularly in individuals who are genetically predisposed. One aspect of the invention comprises administering an agent that effectively neutralizes ghrelin. Another aspect comprises administering a ghrelin receptor (growth hor- ... 09/15/05 - 20050201937 - Temporal or spatial characterization of biosynthetic events in living organisms by isotopic fingerprinting under conditions of imposed isotopic gradients The invention provides methods useful for establishing timing or spatial location of a biosynthetic event in a living organism, without disrupting the event of interest and without disrupting the living organism. A temporal or spatial gradient of an isotopically labeled biochemical precursor is created, which serves to isotopically fingerprint (i.e., ... 09/15/05 - 20050201936 - Models for viral-based cancer therapy The present invention relates to the use of cotton rats and Syrian hamsters as models for adenoviral gene therapy. In particular, the models are directed to the examination of the ability of various replicative, non-replicative and conditionally-replicative adenovirus vectors to treat cancer. ... 09/01/05 - 20050191242 - Foxn1 and pigmentation The present invention provides methods and compositions for modulating skin pigmentation. ... 08/25/05 - 20050186138 - Methods and compositions for modulating circadian rhythm The present invention provides methods of identifying circadian rhythm modulators and methods of modulating circadian rhythm in animals. ... 08/11/05 - 20050175538 - Small animal light intensity monitor Disclosed are methods and apparatus for collecting light emitted from an animal, where a luminescent reporter has been injected into the animal is disclosed. The apparatus includes a chamber for receiving the animal, wherein the chamber is light tight preventing a substantial portion of light emitted from the animal from ... 08/04/05 - 20050169841 - Methods of screening for b cell activity modulators The invention provides for the identification of all genes, whether known or novel, which are differentially expressed within and among B cells, making possible the characterization of their temporal regulation and function in the B cell response and/or in B cell mediated disorders. Expression profiles, nucleic acids and proteins are ... 08/04/05 - 20050169840 - Method for screening modulators of the immune system A method for determining whether a factor is a modulator of the transmission, of immunity from a female mammal to newborn mammals by consumption of milk from the female. A female mammal, such as a BALB/C female mouse, is exposed to the factor, and then immunized to one or more ... 08/04/05 - 20050169839 - Biomarker for efficacy of appetite suppressant drugs The present invention relates to a biomarker for the efficacy of appetite suppressant drugs given to humans or other mammals for the treatment of obesity. It further relates to a novel method of determining the efficacy of a test compound given to a subject for the treatment of obesity, wherein ... 07/28/05 - 20050163712 - Method for identifying bronchoconstriction relaxing substances In a method of measuring a relaxing effect on constricted human bronchi of a candidate substance a bronchus tissue preparation is mounted to a force transducer in a test apparatus. After conditioning the preparation is exposed for a contraction-effective dose of a known contraction-effective substance to make it assume a ... 07/21/05 - 20050158243 - Altering memory by affecting staufen function The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or STAUFEN function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating staufen-dependent ... 07/07/05 - 20050147561 - Method for identifying pesticidal active compounds The present invention relates to a method for identifying pesticidally active substances. The present invention relates in particular to a binding assay with labelled phthalic diamides on membrane preparations and the displacement of these labelled phthalic diamides by unlabelled test substances. ... 06/30/05 - 20050142066 - Compounds or agents that inhibit and induce the formation of focal microvessel dilatations The invention relates to the discovery that inflammation involves a structural modification to the microvascular architecture that results in the formation of focal microvessel dilatations or “microangiectasias.” The focal microvessel dilatations cause localized slowing of blood cell flow velocity that promotes the accumulation of extravascular lymphocytes. Methods are disclosed herein ... 06/30/05 - 20050142065 - Screening method The present invention provides a method of screening for an agent for the treatment of human diabetes mellitus, which comprises administering a test compound to a diabetes mellitus model non-human mammal, and selecting a compound that causes a decrease of not less than 0.5% in a glycated hemoglobin value after ... 06/30/05 - 20050142064 - Method of measuring human cyp3a inducibility A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being ... 06/23/05 - 20050136006 - Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified ... 06/23/05 - 20050136005 - Methods for modulation of cholesterol transport Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically downregulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in ... 06/16/05 - 20050129618 - Drugs for ameliorating itch, rough skin or hypersensitive skin or for whitening via inhibition of the production and release of stem cell factor The invention provides a screening method for active ingredients which exhibit effects of ameliorating pruritus, rough skin or sensitive skin, or effects of skin whitening, by inhibiting production and/or release of stem cell factor (SCF), as well as medicaments for pruritus, rough skin, sensitive skin and/or skin whitening which contain ... ### FreshPatents.com Support |